Indication
In combination with adequate support measures, Agilus is indicated for the treatment of malignant hyperthermia in adults and children of all ages.
Loading your page…
Loading your page…
Malignant Hyperthermia
Marketing Authorisation Holder: Norgine B.V.
EMA Authorisation: 29/05/2024
INN: dantrolene sodium, hemiheptahydrate
AI Drug & Interaction Analysis
Free account required
Ask Osler about Agilus: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.